Background: Surgery is the usual therapy for patients with primary hyperparathyroidism. We investigated the ability of a calcimimetic drug that inhibits parathyroid hormone secretion in vitro to decrease serum parathyroid hormone and calcium concentrations in patients with this disorder.
Methods: We performed a randomized, placebo-controlled study of single oral doses of 4 to 160 mg of the calcium-receptor agonist drug R-568 in 20 postmenopausal women with mild primary hyperparathyroidism. At base line, the mean (+/-SE) serum calcium concentration was 10.7+/-0.2 mg per deciliter (2.67+/-0.05 mmol per liter). Serum parathyroid hormone and calcium were measured repeatedly after each dose, and safety was assessed.
Results: Administration of R-568 resulted in a dose-dependent inhibition of parathyroid hormone secretion. The mean serum parathyroid hormone concentration, which was 77+/-11 pg per milliliter (18.8+/-2.7 pmol per liter; normal range, 16 to 65 pg per milliliter [3.9 to 15.9 pmol per liter) at base line, fell by 26+/-8 percent after 20 mg of R-568 (P=0.03), by 42+/-7 percent after 80 mg (P = 0.01), and by 51+/-5 percent after 160 mg (P=0.005). Serum ionized calcium concentrations fell only after the 160-mg dose, with the decrease closely following the decrease in the serum parathyroid hormone concentration.
Conclusions: The calcimimetic drug R-568 reduces serum parathyroid hormone and ionized calcium concentrations in postmenopausal women with primary hyperparathyroidism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJM199711203372104 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation between parathyroid adenoma volume and perioperative outcomes in primary hyperparathyroidism: Does the size matter?
Updates Surg
January 2025
University Center of Gastrointestinal and Liver Diseases-Clarunis, University of Basel, Basel, Switzerland.
Background: Primary hyperparathyroidism (PHPT) due to a parathyroid adenoma stands as one of the most prevalent endocrinological disorders, with focused parathyroidectomy being the established therapeutic strategy.
Aim: This study aims to investigate whether the volume of the pathological gland influences perioperative outcomes and postoperative morbidity.
Methods: A retrospective analysis was conducted on data from 141 patients who underwent focused parathyroidectomy for PHPT at the University Hospital of Basel between 2007 and 2022.
Diagnostic Ability and Correlation of Digital C-Methionine PET/CT in Primary Hyperparathyroidism with Inconclusive Standard Imaging.
Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Purpose: C-Methionine PET/CT is a promising method for detecting parathyroid lesions in patients with primary hyperparathyroidism (PHPT). We aimed to determine the diagnostic ability and correlation of digital C-Methionine PET/CT for parathyroid lesions in patients with PHPT, particularly in cases where standard imaging methods yielded inconclusive results.
Methods: This retrospective analysis was conducted on patients diagnosed with PHPT who underwent digital C-Methionine PET/CT imaging because of ambiguous results on standard imaging work-up (Tc-MIBI parathyroid scan and/or neck ultrasonography).
Aptamer-Antibody Birecognized Sandwich SERRS Biosensor in Accurate and Rapid Identification of Intraoperative Parathyroid Hormone.
Anal Chem
January 2025
State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, College of Energy, Discipline of Intelligent Instrument and Equipment, Cancer Center and Department of Breast and Thyroid Surgery, Department of Ultrasound, Xiang'an Hospital of Xiamen University, School of Medicine, Laboratory Animal Center Xiamen University, Xiamen University, Xiamen 361005, China.
With the increasing incidence of thyroid cancer worldwide and the increasing demand for surgery, the risk of parathyroid injury is also increasing, which will lead to postoperative hypoparathyroidism (HP) and hypocalcemia. In order to improve the quality of life of patients after surgery, there is an urgent need to develop a novel platform that can identify the parathyroid gland immediately during surgery. The parathyroid gland promotes the increase of blood calcium concentration by secreting parathyroid hormone (PTH).
View Article and Find Full Text PDFAtypical parathyroid tumor: A rare cause of primary hyperparathyroidism in an adolescent.
Arch Argent Pediatr
January 2025
Hospital Italiano de Buenos Aires, City of Buenos Aires, Argentina.
Hyperparathyroidism is a rare entity in pediatrics. It is defined as the increased production of parathyroid hormone. It may be due to a primary defect of the parathyroid glands (primary hyperparathyroidism) or to a compensatory parathyroid hormone production to correct hypocalcemia states of various origins (secondary hyperparathyroidism).
View Article and Find Full Text PDFCorrelation between dental fluorosis risk and bone-specific alkaline phosphatase, osteocalcin, matrix metalloproteinase and parathyroid hormone in children.
J Med Biochem
November 2024
Huzhou University, School of Engineering, Huzhou, Zhejiang, China.
Background: The aim of this study was to investigate the association between dental fluorosis occurrence in children and bone metabolism-related indicators, including bone-specific alkaline phosphatase (BALP), osteocalcin (OC), matrix metalloproteinase (MMP-2, MMP-9, MMP-20), and parathyroid hormone (PTH).
Methods: A total of 189 cases of school-age children who underwent health examinations in our hospital were enrolled, according to the presence or absence of dental fluorosis. They were divided into the fluorosis group (n=97) and fluoride-free group (n=92), and the serum BALP, OC, MMP-2, MMP-9, MMP-20, and PTH levels of the two groups were compared and relevant clinical data were collected.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!